Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity cuts Pets at Home target price but keeps at 'buy'

(Sharecast News) - Canaccord Genuity has trimmed its target price for Pets at Home following last week's abrupt departure of its CEO and cut to full-year guidance, but has kept a 'buy' rating on the stock.. Pets at Home shares tanked on Thursday after the retailer and vets chain announced the immediate exit off CEO Lyssa McGowan after three years, coinciding with the company's second profit warning in as many months.

"Whilst disappointing to have to revise estimates again in such short order, it is another reminder that the UK consumer backdrop remains challenging. That said, management had hoped to outperform the market," Canaccord Genuity said.

However, the broker added: "The business is far from broken, and we continue to believe that investment (DC infrastructure and digital platform) made in recent years provides a strong platform for PETS to outperform and the Group is well-placed to benefit as and when the UK macro backdrop improves, albeit now with a new CEO leading the Group. We expect the Group will look for a new CEO with experience in retail turnaround situations."

With the company now guiding to adjusted pre-tax profits of £90m-100m for the year to end-March, down from £110m-120m previously, Canaccord Genuity has cut its estimates and lowered its target price for the shares from 285p to 245p.

However, the broker pointed out that the stock is trading at just 13.2 times FY26 earnings, falling to 12.6x on FY27 earnings - well below the 10-year average of 15x.

The stock was 2.5% higher at 197.6p by 1243 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.